Laurus Labs Share Price Hits Multi-Year High on Strong FY25 Results and Growth Outlook

Laurus Labs share price hit a multi-year high of ₹717.40 on the BSE during intra-day trading on Monday, June 30, 2025, rising 2% amid strong investor interest. The stock has surged 18% so far this month, far outperforming the BSE Sensex, which rose only 3%.

Currently, the share is trading near its all-time high of ₹723.55, last reached on August 12, 2021. It has gained an impressive 83% from its 52-week low of ₹390.30 recorded on August 8, 2024.

Highlights of Laurus Labs Q4 FY25 Earnings Results

• Laurus Labs reported a strong performance in FY25, with net profit more than doubling to ₹358 crore.
• Revenue grew 10% year-on-year to ₹5,554 crore, driven by strong performance in the CDMO and FDF segments.
• EBITDA increased 40% to ₹1,115 crore, with a healthy EBITDA margin of 20.1%.
• Gross margin remained robust at 55.4%, supported by a favourable product mix.
• The company completed over 160 quality audits — a 20% increase over the previous year — with no critical findings.
• Laurus also received inspection approvals for its Unit 4 API facility in Visakhapatnam.

Laurus Labs Future Plans

Laurus Labs is also planning to grow its Generic FDF division by expanding its non-ARV portfolio, particularly in North America. It is aiming to expand its global presence in the CDMO space by increasing capacity and investing in advanced technologies. The company is also exploring high-value services like biologics and gene therapy.

The Indian CDMO market is expected to double by 2029, offering Laurus significant growth opportunities. The company’s strong order book, especially in the antiretroviral (ARV) API segment, supports a positive future outlook. Moreover, automation and AI-driven process optimisation will also play a key role in boosting productivity and compliance.

Read more: Best Flexi Cap Funds in July 2025: Kotak Flexicap, Parag Parekh Flexi Cap and More Based on 3Y CAGR

Conclusion

With a strong FY25 performance, increased investor confidence, and a clear growth path ahead, Laurus Labs is well-positioned to become a leading global CDMO and generic pharmaceutical partner. Its focus on innovation, quality, and operational strength makes it a company to watch in the Indian pharma space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.